Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials

Prospective, single-blind, placebo-controlled, three-treatment, three-period, adaptive multi-centre Phase IIa (proof-of-concept) trial to investigate the efficacy, safety, and tolerability of Ketamine HCl PR tablets in patients with chronic non-malignant neuropathic pain

To see complete record on, please visit this link

Id: 2014-004535-40

Organisation Name: Develco Pharma Schweiz AG

Start Date: 2015-04-21

Completion Date: Completed

Brief Summary: The primary objective of the trial is to investigate the effect of Ketamine HCl PR tablets administered twice daily as add-on therapy to the individual standard treatment regimen of each patient in comparison to placebo in the relief of chronic non-malignant neuropathic pain as determined by absolute changes in the “current” pain intensity (PI) score on the visual analogue scale (VAS).

Country: Switzerland

Total execution time in seconds: 0.1963529586792